
64Cu-SAR-bisPSMA Earns FDA Breakthrough Designation in Recurrent Prostate Cancer
The FDA granted breakthrough therapy designation to 64Cu-SAR-bisPSMA for PSMA PET imaging in men with suspected biochemical recurrence of prostate cancer.
The FDA has granted breakthrough therapy designation to copper Cu 64 (64Cu)-SAR-bisPSMA for PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer who have suspected recurrence based on elevated serum prostate-specific antigen (PSA) levels, according to a news release from the developer, Clarity Pharmaceuticals.1 According to the company, this is the first breakthrough therapy designation granted to a PSMA PET imaging agent.
The designation was supported by data from the
What data supported the breakthrough designation for 64Cu-SAR-bisPSMA?
The investigator-initiated Co-PSMA trial compared 64Cu-SAR-bisPSMA with standard gallium Ga 68 (68Ga)–PSMA-11 PET/CT in 50 patients with biochemical recurrence (BCR) following radical prostatectomy, with a median PSA of 0.43 ng/mL.1 The trial met its primary end point, with a mean of 1.26 lesions detected per patient with next-day (24-hour) 64Cu-SAR-bisPSMA imaging vs 0.48 lesions with 68Ga-PSMA-11 (P <.0001). Patient-level positivity was 78% (n = 39/50) vs 36% (n = 18/50), respectively, and reader agreement was higher with 64Cu-SAR-bisPSMA (Cohen κ, 0.94 vs 0.75). Planned management changed in 44% of patients after 64Cu-SAR-bisPSMA imaging. Findings were published in European Urology.2
In the single-arm COBRA trial, which enrolled patients with BCR and negative or equivocal findings on conventional imaging, with a median PSA of 0.9 ng/mL, the patient-level detection rate ranged from 44% to 58% with same-day imaging and from 58% to 80% with next-day imaging across readers. Next-day imaging identified a median of approximately 91% more lesions than same-day imaging, and investigators reported planned treatment changes in about 48% of patients.
For context, FDA labeling for 68Ga-PSMA-11 and 18F-DCFPyL (piflufolastat F 18; Pylarify) reports positivity rates of 36% and 35%, respectively, in patients with BCR and PSA levels below 0.5 ng/mL, according to the release.
How does 64Cu-SAR-bisPSMA differ from current PSMA PET agents?
SAR-bisPSMA is a bivalent agent that links 2 PSMA-targeting molecules to the company’s sarcophagine (SAR) chelator, which is designed to retain copper isotopes and prevent copper leakage into the body. Copper-64 has a half-life of 12.7 hours, enabling imaging up to approximately 30 hours after injection, compared with the 1- to 2-hour half-lives of gallium-68 and fluorine-18. The same platform can carry copper-67 for therapeutic use.
Alan Taylor, PhD, executive chairperson of Clarity Pharmaceuticals, stated in the press release that “currently approved products miss metastatic disease in many patients, particularly in those with small volume disease.”1
Breakthrough therapy designation includes all features of fast track designation, intensive FDA guidance on the development program, and the involvement of senior FDA managers, and it may support eligibility for priority review at the time of a new drug application.
What are the phase 3 AMPLIFY and CLARIFY trials evaluating?
AMPLIFY is a single-arm, open-label, multicenter diagnostic trial in the US and Australia enrolling patients with rising or detectable PSA (>0.2 ng/mL) after initial definitive treatment. The co-primary end points are participant-level correct detection rate and region-level positive predictive value for same-day (1 to 4 hours) and next-day (approximately 24 hours) imaging. The trial reached its target of approximately 220 patients in March 2026.
CLARIFY is a single-arm, open-label diagnostic trial with blinded review evaluating 64Cu-SAR-bisPSMA in patients with untreated, histopathology-confirmed high-risk prostate cancer before radical prostatectomy with pelvic lymph node dissection. Target enrollment was reached in October 2026.
Both trials have completed recruitment and are in follow-up, according to Clarity. The company plans to use the results to support an FDA application for 64Cu-SAR-bisPSMA as a diagnostic imaging agent in both the BCR and pre–definitive therapy settings.
References
- First FDA breakthrough therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer. News release. Clarity Pharmaceuticals. November 12, 2026. Accessed November 16, 2026. https://tinyurl.com/6fs8hch2
- Khan S, Papa N, Kneebone A, et al. Prospective comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium[68Ga] PSMA-11 PET/CT for biochemical recurrence of prostate cancer following radical prostatectomy (Co-PSMA Trial). Eur Urol.2026;89(6):512-520. doi:10.1016/j.eururo.2026.03.001
Related to this article








